Searched for
BIOCON EQUITY RAISE
The 20 stocks mutual funds are buying with Rs 1 lakh crore to defy historic FII sellingIndian mutual funds are investing Rs 1.07 lakh crore in 20 key stocks to counter historic FII selling. They are focusing on large-cap priva...- Jio Financial, ITC Hotels and Manappuram Finance among stocks bought and sold by mutual funds in AprilMutual funds injected Rs 30,600 crore into Indian equities in April, with significant buying in ICICI Bank, SBI, and Sun Pharma. Key reduct...
- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- S&P Global upgrades Biocon Biologics credit rating To 'BB+'Biocon Biologics has received a credit rating upgrade from S&P Global Ratings. The company's long-term issuer credit rating is now 'BB+' wi...
- S&P Global upgrades Biocon Biologics ratingsS&P Global Ratings on Wednesday upgraded Biocon Biologics ratings with a stable outlook.
- Biocon reports 95% YoY decline in net profit, operating revenue up 15%Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3...
- Biocon sets floor price of Rs 340.2 per share for Rs 4,500 cr QIPBiotechnology firm Biocon Ltd on Monday said it has set the floor price of Rs 340.2 per equity share for its qualified institutions placeme...
- Biocon Biologics is planning to raise $950 million through overseas bondsBiocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from a...
- Biocon Biologics to raise debt of Rs 4,500 crore for Viatris PayoutBiocon Biologics plans to raise ₹4,500 crore with HSBC and MUFG's aid for a $175 million Aflibercept option. Previous funding by Kotak and ...
- 'Biocon looking at options to cut debt taken for Viatris' business buy'"We are looking at a number of options to reduce that... I can say that you'll see the debt level coming down in the coming quarters," he s...
- Biocon Biologics may raise additional equity of $300 million in FY24 to pare debtBiocon Biologics plans to raise a further $300m by the end of FY24 in order to reduce its net debt, which peaked at $1.9bn in December 2022...
- Serum Institute to double investment in Biocon Biologics to $300 millionSerum Institute of Life Sciences (SILS) has converted a $150 million loan into equity, increasing its investment in Biocon Biologics. This ...
- Biocon Biologics has comprehensive plan to integrate Viatris business: Shreehas Tambe, Biocon Biologics"There are several other discussions that we have been having with private equity investors who are interested in making an investment in B...
- Biocon raises $1.2 billion green loan to fund purchase of Viatris unitBiocon agreed to meet certain sustainability targets that helped reduce the cost of the loan. According to sources, the loan came at a cost...
- Biocon Biologics allots equity shares worth Rs 2,205.63 crore to its parentAt the time of announcing the deal to acquire Viatris, BBL had said it would be through a cash payment of USD 2 billion, which would be fun...
- Biocon Biologics secures regulatory approvals for acquisition of Viatris' biosimilar businessThe transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...
- Biocon Biologics eyes $200m, plans IPO in 2 years: Mazumdar-ShawIt looks to build a pipeline of 28 biosimilars across global markets in three phases.
- Biocon elevates M B Chinappa as CFO of biosimilar subsidiaryM B Chinappa, who is going to play an important role in Biocon Biologics’ journey towards becoming a global leader in biologics, has been t...
- Syngene gets FIPB nod to raise foreign investment to 44%Syngene, a subsidiary of Biocon, said it has received the Foreign Investment Promotion Board approval to raise foreign investment to 44 per...
- Biocon surges as company files prospectus for Syngene IPO to raise Rs 600 crore; ends in redBiocon surged over 3% in intraday trade on Thursday after the company filed prospectus for Syngene IPO on Wednesday to raise Rs 600 cr .
Load More
